<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981887</url>
  </required_header>
  <id_info>
    <org_study_id>W-4873-105</org_study_id>
    <nct_id>NCT03981887</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Intravenous Nafithromycin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wockhardt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinartis, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keystone Bioanalytical, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wockhardt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase 1, randomized, double-blind, single-center, placebo-controlled study in
      healthy male and female adult subjects. Subjects will be randomly assigned to receive either
      nafithromycin or placebo by intravenous (IV) infusion based on a double-blind randomization
      schedule. The following treatments will be administered:

        -  Nafithromycin 200 mg or placebo administered as IV infusions twice daily (q12h) over a
           period of 3 hours for 3 days.

        -  Eight subjects (n=8) will receive nafithromycin and 2 subjects (n=2) will receive
           placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Actual">August 7, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety</measure>
    <time_frame>Day 19</time_frame>
    <description>By measuring treatment emergent AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess multiple dose drug tolerability</measure>
    <time_frame>Day 19</time_frame>
    <description>By measuring treatment emergent AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess plasma PK parameters profile</measure>
    <time_frame>Day 3</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess plasma PK parameters profile</measure>
    <time_frame>Day 3</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess plasma PK parameters profile</measure>
    <time_frame>Day 3</time_frame>
    <description>Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess plasma PK parameters profile</measure>
    <time_frame>Day 3</time_frame>
    <description>Terminal half-life (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Nafithromycin 200 mg as IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nafithromycin 200 mg administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo administered as IV infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as IV infusions twice daily (q12h) over a period of 3 hours for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafithromycin</intervention_name>
    <description>Nafithromycin 200 mg as IV infusion</description>
    <arm_group_label>Nafithromycin 200 mg as IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo administered as IV infusion</description>
    <arm_group_label>placebo administered as IV infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥18 to ≤32 kg/m2, both inclusive.

          -  Stable health based on a medical history without any major pathology/surgery in the 6
             months before Screening and no clinically significant physical examination findings or
             clinical laboratory test results

          -  Resting supine blood pressure of 90 to 139 mmHg (systolic) and 60 to 89 mmHg
             (diastolic) and a resting heart rate of 50 to 100 beats per minute at Screening and
             Check-in (Day -1).

          -  Calculated creatinine clearance ≥80 mL/min (Cockroft-Gault method) at Screening.

          -  Computerized 12-lead electrocardiogram (ECG) recording without signs of clinically
             significant pathology and showing no clinically significant deviation as judged by the
             investigator

        Exclusion Criteria:

          -  Participation in another investigational drug or device study or treated with an
             investigational product within 30 days or 5 half-lives, whichever is longer, before
             study drug administration in this study.

          -  History/evidence of clinically relevant pathology

          -  History of clinically significant food or drug allergy

          -  Positive alcohol or urine drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Sanabria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical Research LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

